Outcomes among Adult Recipients of CAR T-Cell Therapeutics for Burkitt and Burkitt-like Lymphoma Read more
Outcomes of Patients with Relapsed/Refractory Hodgkin Lymphoma Treated with PD-1 Inhibitors Outside of Clinical Trials Read more
Outcomes of Patients with Newly Diagnosed Peripheral T-cell Lymphoma Treated with Aggressive Chemotherapy, including Cutaneous Gamma-Delta T cell Lymphoma Read more
A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients With Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) Read more
Characteristics and Outcomes of Patients with Marginal Zone Lymphoma: A Retrospective Study Read more
Real world outcomes patients with large B-cell lymphoma receiving curative intent therapies profiled with clonotype circulating tumor DNA sequencing Read more
A Phase 2 Study of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed by BV Consolidation in Patients with CD30-Positive Peripheral T-Cell Lymphomas Read more
